Atour Lifestyle Holdings Limited (ATAT)

CTI BioPharma Income Statement

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Operating Revenue	7,483	7,049	4,518	2,167	2,042	1,567
Other Revenue	202.77	199.02	148.38	95.6	105.44	-
Revenue	7,685	7,248	4,666	2,263	2,148	1,567
Revenue Growth (YoY)	43.38%	55.34%	106.19%	5.37%	37.09%	-0.03%
Cost of Revenue	4,397	4,192	2,754	1,545	1,541	1,150
Gross Profit	3,288	3,056	1,912	717.86	606.63	416.45
Selling, General & Admin	1,519	1,325	921.07	489.94	333.17	258.62
Research & Development	149.22	134.02	77.29	66.18	52.12	33.65
Other Operating Expenses	-32.65	-25.71	-10.64	-3.22	19.59	55.32
Operating Expenses	1,635	1,434	987.72	552.9	410.58	365.85
Operating Income	1,653	1,622	924.03	164.96	196.06	50.6
Interest Expense	-3.05	-3.11	-5.01	-6.5	-7.94	-1.48
Interest & Investment Income	54.18	48.42	29.57	14.46	6.72	0.71
Other Non Operating Income (Expenses)	-3.18	2.47	-1.02	-0.81	0.3	1.88
EBT Excluding Unusual Items	1,701	1,670	947.57	172.1	195.14	51.71
Gain (Loss) on Sale of Investments	49.2	48.94	34.52	8.46	8.75	11.05
Other Unusual Items	-	-	-	-	-	12.67
Pretax Income	1,750	1,719	982.09	180.56	203.89	75.42
Income Tax Expense	491.22	446.03	243.04	84.47	64.22	37.6
Earnings From Continuing Operations	1,259	1,273	739.06	96.08	139.67	37.82
Minority Interest in Earnings	2.04	2.36	-1.92	2.02	5.38	4.23
Net Income	1,261	1,275	737.14	98.1	145.05	42.05
Preferred Dividends & Other Adjustments	-	-	-	-	15.12	52.88
Net Income to Common	1,261	1,275	737.14	98.1	129.94	-10.83
Net Income Growth	29.13%	73.01%	651.42%	-32.37%	244.95%	-35.27%
Shares Outstanding (Basic)	138	138	135	126	108	57
Shares Outstanding (Diluted)	139	139	138	127	108	57
Shares Change (YoY)	0.51%	0.58%	8.71%	18.08%	88.33%	-
EPS (Basic)	9.13	9.25	5.45	0.78	1.21	-0.19
EPS (Diluted)	9.06	9.18	5.34	0.78	1.20	-0.19
EPS Growth	28.10%	71.91%	588.28%	-35.35%	-	-
Free Cash Flow	1,522	1,670	1,947	247.25	353.91	5.92
Free Cash Flow Per Share	10.93	12.01	14.08	1.94	3.29	0.10
Dividend Per Share	3.285	3.285	1.064	-	-	-
Dividend Growth	208.82%	208.82%	-	-	-	-
Gross Margin	42.79%	42.16%	40.97%	31.72%	28.25%	26.58%
Operating Margin	21.51%	22.38%	19.80%	7.29%	9.13%	3.23%
Profit Margin	16.41%	17.60%	15.80%	4.33%	6.05%	-0.69%
Free Cash Flow Margin	19.80%	23.04%	41.73%	10.93%	16.48%	0.38%
EBITDA	1,714	1,688	1,009	253.52	288.67	134.6
EBITDA Margin	22.30%	23.28%	21.63%	11.20%	13.44%	8.59%
D&A For EBITDA	61.29	65.23	85.02	88.56	92.61	84
EBIT	1,653	1,622	924.03	164.96	196.06	50.6
EBIT Margin	21.51%	22.38%	19.80%	7.29%	9.13%	3.23%
Effective Tax Rate	28.07%	25.95%	24.75%	46.78%	31.50%	49.85%
Revenue as Reported	7,685	7,248	4,666	2,263	2,148	1,567

Updated May 22, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q